Merck Arcoxia Acute Gout Trials Used Appropriate Comparator, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The sponsor's comparison of etoricoxib to indomethacin in Phase III trials for acute gout was "as good as it gets" with the limited data available on existing therapies, FDA's Arthritis Advisory Committee says. Acute gout trials should use an active comparator with pain as the primary endpoint, the committee suggests.